title: Topical Imiquimod for the Treatment of Childhood Cutaneous Langerhans Cell Histiocytosis.
abstract: Although topical steroids are considered first-line treatment for cutaneous Langerhans cell histiocytosis (LCH), the appropriate therapy for refractory cases remains controversial. We report a 16-month-old girl with isolated cutaneous LCH refractory to treatment with topical corticosteroids and topical tacrolimus. Treatment was initiated with 5% topical imiquimod cream and the rash completely resolved after 5 months of therapy. There was no disease recurrence after more than 2 years of follow-up. We present this case to highlight imiquimod as a novel therapeutic agent for the management of isolated cutaneous LCH in children.
authors.affiliation: Medical School, University of Minnesota, Minneapolis, Minnesota.
authors.forename: Erin
authors.initials: E
authors.lastname: Dodd
authors.affiliation: Department of Dermatology, University of Minnesota, Minneapolis, Minnesota.|Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
authors.forename: Kristen
authors.initials: K
authors.lastname: Hook